Patents Assigned to Quest Diagnostics Investments Incorporated
  • MLH1 METHYLATION ASSAY
    Publication number: 20180291426
    Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter C region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.
    Type: Application
    Filed: April 22, 2016
    Publication date: October 11, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Amber C. Donahue, Feras Hantash
  • Methods for detecting gene dysregulation by intragenic differential expression
    Patent number: 10093985
    Abstract: Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g., translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5? and 3? regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 9, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
  • BCR-ABL truncation mutations
    Patent number: 10093980
    Abstract: Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: October 9, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Maher Albitar, Wanlong Ma
  • DETECTION OF GENE FUSIONS BY INTRAGENIC DIFFERENTIAL EXPRESSION (IDE) USING AVERAGE CYCLE THRESHOLDS
    Publication number: 20180274040
    Abstract: Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene. The average expression of the 5? portion of the target gene is compared with the average expression of the 3? portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.
    Type: Application
    Filed: March 9, 2018
    Publication date: September 27, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Shih-Min CHENG
  • Methods of detecting reverse triiodothyronine by mass spectrometry
    Patent number: 10079138
    Abstract: Provided are methods for determining the amount of reverse T3 in a sample using mass spectrometry. The methods generally involve ionizing reverse T3 in a sample and detecting and quantifying the amount of the ion to determine the amount of reverse T3 in the sample.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: September 18, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: J. Fred Banks, Peter P. Chou, Noriya M. Matt
  • Molecular detection of enterovirus and parechovirus
    Patent number: 10072308
    Abstract: Provided herein are methods for determining the presence or absence of an enteroviruses and parechoviruses in a biological sample. The methods involve identifying the presence or absence of a target nucleic acids from the viruses using direct amplification from a biological sample without a step of extraction of the nucleic acids, but retaining substantially the same specificity and sensitivity of methods assaying extracted nucleic acids. Also provided are methods of diagnosis using the methods provided and compositions and kits for the practice of the methods.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: September 11, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Peter Lee, Lakshmi Nair, Albert Castro, Maria Vestal, Michelle Tabb
  • Hematopoietic cell phenotyping using circulating cell-free markers
    Patent number: 10067133
    Abstract: The present invention provides methods of classifying cluster of differentiation (CD) marker phenotype for hematopoietic cancer cells using multiple circulating cell-free CD markers in bodily fluid. In other aspects, treatment and disease progression of particular hematopoietic cancers can be monitored by measuring the levels of CD and other markers in bodily fluids of a patient.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 4, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Maher Albitar
  • RNA isolation from soluble urine fractions
    Patent number: 10066226
    Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 4, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Heather Sanders, Hai-Rong Li
  • MicroRNA profiling for diagnosis of dysplastic nevi and melanoma
    Patent number: 10053738
    Abstract: Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: August 21, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Kevin Qu, Anthony Sferruzza, Ke Zhang, Yan Liu, Renius Owen
  • CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE MUTATIONS
    Publication number: 20180208987
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. The mutations include duplication of exons including duplication of exons 6b through 10. Methods of identifying if an individual contains the exons 6b through 10 duplication are provided as well as nucleic acid fragments that contain the junction site of the duplicated segment. The detection of additional mutations in the CFTR gene are also provided.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 26, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventor: Feras Hantash
  • Detection of complex nucleic acids
    Patent number: 10030276
    Abstract: Disclosed is a method for determining the presence of Mycobacterium tuberculosis complex nucleic acids in a test sample. In particular, regions of the IS6110 preferential locus (ipl) 3?-flanking region of the Mycobacterium tuberculosis complex genome are amplified and detected. In addition, oligonucleotides that can be used as primers to amplify the ipl 3?-flanking region and probe oligonucleotides are described.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: July 24, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Maurice Exner
  • CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE MUTATIONS
    Publication number: 20180195129
    Abstract: The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided.
    Type: Application
    Filed: March 2, 2018
    Publication date: July 12, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Weimin SUN, Matthew J. McGinniss, Donghui Huang, Arlene Buller, Raymond Fenwick, Mei Peng, Franklin Quan
  • SYSTEMS AND METHODS FOR ELECTRONICALLY DISTRIBUTING INFORMATION
    Publication number: 20180176159
    Abstract: Embodiments of the invention include systems and methods for transmitting messages related to certain information while maintaining the confidentiality of that information. A potential recipient may register one or more devices for receipt of such messages while specifying rules regarding when different messages may be delivered to the various devices. To keep sensitive information confidential, the messages may include only a link to such sensitive information, but exclude the sensitive information itself. An authorized recipient may then use the link to access the sensitive information via a password-protected Web site.
    Type: Application
    Filed: February 20, 2018
    Publication date: June 21, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Douglas Menkedick, David Rapperport, Maheswar Putta
  • CIRCULATING MICRORNA AS A MARKER FOR HEPATOCELLULAR CARCINOMA
    Publication number: 20180163274
    Abstract: Provided herein are methods for the diagnosis, or management of liver diseases, e.g., hepatocellular carcinoma, using profiles of the miRNAs determined from cellular or acellular body fluids.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 14, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Kevin Qu, Ke Zhang, Maher Albitar
  • Microrna profiling for diagnosis of dysplastic nevi and melanoma
    Patent number: 9988689
    Abstract: Provided herein are methods for miRNA profiling for the diagnosis, prognosis, and management of melanoma and differentiation of melanoma from nevi.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: June 5, 2018
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Kevin Qu, Anthony Sferruzza, Ke Zhang, Yan Liu, Renius Owen
  • COMPOSITIONS AND METHODS FOR SCREENING SOLID TUMORS
    Publication number: 20180142304
    Abstract: The present technology relates to methods for determining whether a patient diagnosed with breast cancer, colorectal cancer, melanoma or lung cancer will benefit from or is predicted to be responsive to treatment with an individual therapeutic agent or a specific combination of therapeutic agents. These methods are based on screening a patient's solid tumors and detecting alterations in target nucleic acid sequences corresponding to a specific set of cancer-related genes. Kits for use in practicing the methods are also provided.
    Type: Application
    Filed: October 28, 2015
    Publication date: May 24, 2018
    Applicant: Quest Diagnostics Investments Incorporated
    Inventors: Heather SANDERS, Kevin QU, James PRENTICE, Frederic WALDMAN
  • Diagnosis of prostate cancer
    Patent number: 9963695
    Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: May 8, 2018
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventor: Heather R. Sanders
  • C peptide detection by mass spectrometry
    Patent number: 9964546
    Abstract: Methods are described for measuring the amount of C peptide in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying C peptide in a sample utilizing on-line extraction methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: May 8, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Nigel Clarke, Zhaohui Chen
  • Graphical presentation of medical data
    Patent number: 9966153
    Abstract: Methods and user interfaces are provided for the display of data comprising series of data over time, with particular application to medical laboratory results and prescriptions of medication. A user may view multiple results simultaneously in a single display, with the abilities to zoom the time scale in and out and to select the time period for which results are displayed. Multiple displayed items of data may be selected for simultaneous display along a common time axis in a zoomable graph, facilitating interpretation of relationships between and/or among data items.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: May 8, 2018
    Assignee: Quest Diagnostics Investments Incorporated
    Inventor: Kavya Ramachandran
  • EML4-ALK translocations in lung cancer
    Patent number: 9957573
    Abstract: The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: May 1, 2018
    Assignee: QUEST DIAGNOSTICS INVESTMENTS INCORPORATED
    Inventors: Heather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig